Pheochromocytoma
Conditions
Brief summary
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with pheochromocytoma.
Detailed description
Pheochromocytoma highly expresses norepinephrine transporter (NET) which is targeted by function alanalogue of norepinephrine, 123/131I-MlBG. However, low spatial resolution of 123/131I-MlBG and inaccurate attenuation correction of single photon emission tomography (SPECT/CT) will affect the image quality of MlBG SPECT and lead to poor diagnosis of small lesions. In addition, 123l-MlBG imaging is usually performed at 24h after injection, while 131I-MlBG is performed at 48h or even 72h after injection. The procedure is complicated and takes a long time, which limits clinical application. 18F-labeled MFBG is an ideal tracer to show the expression of NET. Preliminary data show that 18F-MFBG imaging is safe and has favorable biodistribution and kinetics with good targeting of lesions. Patients can undergo PET 0.5 hours after injection without special preparation. Our study will assess the safety profile, image quality and evaluate the diagnostic performance and tumor burden of 18F-MFBG. Patients with suspected or histologically confirmed pheochromocytoma will be enrolled in this study.
Interventions
DRUG18F-MFBG
Patients with pheochromocytoma malignancies receive 5.55 MBq/kg of 18F-MFBG intravenously followed by PET/CT or PET/MR after 60min of injection.
Sponsors
First Affiliated Hospital of Zhejiang University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Aged 30-80 years old, primary school or above, with a regular caregiver; 2. Clinically diagnosed patients with pheochromocytoma; 3. Can provide informed consent, can understand and comply with the study requirements.
Exclusion criteria
1. Patients with serious primary diseases such as heart, brain, liver, kidney and hematopoietic system; 2. Uncontrolled hypertension or high-risk BP (i.e., systolic BP \> 180 mmHg or diastolic BP \> 110 mmHg); 3. Patients with mental disorders or primary affective disorders; 4. Unable to understand and adhere to the study protocol or provide informed consent; 5. Contraindications to PET imaging (including pregnant women, lactating women, and women of childbearing age with recent childbearing plans, etc.); 6. Allergy to imaging agents; 7. Patients who were unable to cooperate with PET scanning, such as hypoglycemia, severe pain or tremor.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between positive and negative 18F-mFBG PET/CT or PET/MR Imaging and pathological diagnosis and treatment effect in patients with pheochromocytoma. | through study completion, an average of 1 year | Main outcome measure |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| False positive and false negative results of 18F-mFBG PET/CT or PET/MR Imaging in patients with pheochromocytoma. | through study completion, an average of 1 year | Secondary outcome measure |
Countries
China
Contacts
Primary ContactPeipei Wang, MD
Outcome results
None listed